HomeCompareLUFFF vs ABBV

LUFFF vs ABBV: Dividend Comparison 2026

LUFFF yields 6722.69% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LUFFF wins by $1115813591664363.00M in total portfolio value
10 years
LUFFF
LUFFF
● Live price
6722.69%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1115813591664363.13M
Annual income
$1,084,091,579,851,245,900,000.00
Full LUFFF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — LUFFF vs ABBV

📍 LUFFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLUFFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LUFFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LUFFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LUFFF
Annual income on $10K today (after 15% tax)
$571,428.57/yr
After 10yr DRIP, annual income (after tax)
$921,477,842,873,559,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, LUFFF beats the other by $921,477,842,873,559,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LUFFF + ABBV for your $10,000?

LUFFF: 50%ABBV: 50%
100% ABBV50/50100% LUFFF
Portfolio after 10yr
$557906795832181.63M
Annual income
$542,045,789,925,622,940,000.00/yr
Blended yield
97.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

LUFFF
No analyst data
Altman Z
-10.9
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LUFFF buys
0
ABBV buys
0
No recent congressional trades found for LUFFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLUFFFABBV
Forward yield6722.69%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1115813591664363.13M$102.3K
Annual income after 10y$1,084,091,579,851,245,900,000.00$24,771.77
Total dividends collected$1113685462685399.13M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LUFFF vs ABBV ($10,000, DRIP)

YearLUFFF PortfolioLUFFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$682,969$672,268.91$11,550$430.00+$671.4KLUFFF
2$43,640,941$42,910,164.62$13,472$627.96+$43.63MLUFFF
3$2,609,229,475$2,562,533,667.93$15,906$926.08+$2609.21MLUFFF
4$145,979,000,305$143,187,124,766.75$19,071$1,382.55+$145978.98MLUFFF
5$7,643,033,186,952$7,486,835,656,625.70$23,302$2,095.81+$7643033.16MLUFFF
6$374,522,719,905,465$366,344,674,395,426.06$29,150$3,237.93+$374522719.88MLUFFF
7$17,177,902,473,432,718$16,777,163,163,133,870.00$37,536$5,121.41+$17177902473.40MLUFFF
8$737,542,327,508,684,200$719,161,971,862,111,100.00$50,079$8,338.38+$737542327508.63MLUFFF
9$29,646,740,012,259,066,000$28,857,569,721,824,776,000.00$69,753$14,065.80+$29646740012259.00MLUFFF
10$1,115,813,591,664,363,200,000$1,084,091,579,851,245,900,000.00$102,337$24,771.77+$1115813591664363.00MLUFFF

LUFFF vs ABBV: Complete Analysis 2026

LUFFFStock

Herbal Dispatch owns and operates leading cannabis e-commerce platforms and is dedicated to providing top quality cannabis to informed consumers at affordable pricing. Herbal Dispatch's flagship cannabis marketplace, Herbal Dispatch, is a trusted source for exclusive access to small-batch craft cannabis flower and a wide-array of other product formats.

Full LUFFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this LUFFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LUFFF vs SCHDLUFFF vs JEPILUFFF vs OLUFFF vs KOLUFFF vs MAINLUFFF vs JNJLUFFF vs MRKLUFFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.